<div id="readability-page-1"><h3>End of Quarter Sale - 50% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>The latest update is out from SSY Group ( (HK:2005) ). SSY Group Limited is a Hong Kong-based pharmaceutical group active in China, specializing in the development and manufacture of bulk drugs and related preparations. The company targets major chronic and inflammatory conditions, aiming to deepen its presence in the domestic market for advanced, specialty therapies. The Group announced that its Upadacitinib, a JAK-1 inhibitor used to treat rheumatoid arthritis, Crohn’s disease, atopic dermatitis and several other autoimmune and inflammatory disorders, has received registration approval from China’s National Medical Products Administration as a bulk drug for market preparations. This marks the third such approval granted to a PRC entity and is expected to enhance SSY’s product portfolio in immunology, potentially improving its competitive standing and opening additional revenue opportunities in China’s fast-growing market for targeted autoimmune treatments. The most recent analyst rating on (HK:2005) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page. More about SSY Group SSY Group Limited is a pharmaceutical company based in Hong Kong, operating through subsidiaries in China. The Group focuses on the research, development and production of bulk drugs and preparations, targeting important therapeutic areas in the domestic healthcare market. Its portfolio includes treatments for autoimmune and inflammatory diseases, positioning the company within China’s growing market for advanced specialty pharmaceuticals. The company leverages regulatory approvals from Chinese health authorities to expand its product offerings and strengthen its competitive position. By obtaining registrations for key active pharmaceutical ingredients, SSY seeks to supply both its own finished dosage products and potentially other manufacturers, supporting growth in high-value, patented or differentiated therapies. Average Trading Volume: 8,260,550 Technical Sentiment Signal: Sell Current Market Cap: HK$7.08B </div>

520500

588130

588860

SSY Group Limited has received approval from China's National Medical Products Administration for its Upadacitinib bulk drug, a JAK-1 inhibitor for treating autoimmune disorders. This marks the third approval for a PRC entity and is expected to enhance SSY's product portfolio in immunology, improving its competitive position in China's growing market for targeted treatments. The stock currently holds a Hold rating with a price target of HK$3.00 and a market cap of HK$7.08B.

Tip Ranks

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

ICBCCS SSE STAR Biology and Medicine ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

China Southern Hang Seng Biotech ETF(QDII)

Hwabao WP CSI Pharmaceuticals ETF

Penghua SSE STAR Biology and Medicine ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE Health Care ETF Initiating Fund

SSY GROUP

E Fund CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

E Fund CSI 300 Health Care ETF

Huaan Hang Seng Biotech ETF

Penghua CSI HK Connect Health Care Composite ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Bosera Hang Seng Health Care ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Guotai CSI Bio-medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Tianhong CNI BIOMEDICINE ETF

E Fund Hang Seng SCHK Innovative Drug ETF

SSY Group Wins China Approval for Upadacitinib Bulk Drug